TriangleNCT00507767 · OUTCOME
Number of Participants With Progression-free Survival at 12-weeks
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- At 12-weeks
What was measured
Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.
Analysis population: Analysis per protocol.
Groups in this outcome
Dasatinib
100 mg orally twice daily
| Group | Source count |
|---|---|
| Dasatinib | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Dasatinib | 1 | Not reported | .2 | .05 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- .2
- upper Limit
- .05
- value
- 1
- denoms
- counts
- group Id
- OG000
- value
- 15
- units
- Participants
- description
- Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.
- groups
- description
- 100 mg orally twice daily
- id
- OG000
- title
- Dasatinib
- param Type
- NUMBER
- population Description
- Analysis per protocol.
- time Frame
- At 12-weeks
- title
- Number of Participants With Progression-free Survival at 12-weeks
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice